Navigation Links
Researchers who helped millions with arthritis receive prestigious Janssen Award
Date:5/12/2008

Two British researchers who pioneered treatments which have helped millions of people with rheumatoid arthritis and other autoimmune diseases have been awarded the prestigious 2008 Dr. Paul Janssen Award for Biomedical Research, announced today.

Emeritus Professor Sir Ravinder Maini and Professor Marc Feldmann, who have been carrying out research together at Imperial College London since the 1980s, were selected for the $100K award by an international committee including Nobel Laureates and other world-renowned scientists.

Their research has led to the development of new drugs which tackle the inflammation and tissue destruction caused by rheumatoid arthritis and other diseases including ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohns disease and ulcerative colitis.

The treatments they developed, now used by millions of people across the world, have proved effective in most patients, even those resistant to all previous treatments. They also protect the joints from further destruction.

Previous treatment options for rheumatoid arthritis left almost half of all patients with symptoms of continuing disease, deterioration of physical function and progressive joint damage.

The breakthrough came for Professors Maini and Feldmann when they discovered how autoimmune diseases such as arthritis cause the immune system to fight itself. Their work showed that the key lay in molecules responsible for cell communication, known as cytokines.

Cytokines are normally released by immune cells, to alert the immune system to initiate a protective counter-response against infections. Professors Maini and Feldmann discovered that in autoimmune diseases, cytokines are over-produced, with highly increased cytokine levels around otherwise healthy cells. This leads to the signs and symptoms of disease and in rheumatoid arthritis it explains the body's aggressive reaction in areas of arthritic inflammation around p
'/>"/>

Contact: Laura Gallagher
L.Gallagher@imperial.ac.uk
44-020-759-46702
Imperial College London
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Carnegie Mellon engineering researchers automate analysis of protein patterns
2. Health researchers in McGill network receive $35.5 million in CIHR funding
3. Hopkins researchers discover new link to schizophrenia
4. Researchers find gene location that gives rise to neuroblastoma, an aggressive childhood cancer
5. Researchers Find Gene Location That Gives Rise to Neuroblastoma, an Aggressive Childhood Cancer
6. Researchers Publish Genome Sequence for Duck-Billed Platypus
7. UC San Diego researchers target tumors with tiny nanoworms
8. Researchers Find Lubricant Doesnt Hinder Fertility
9. MGH researchers report successful new laser treatment for vocal-cord cancer
10. Stanford researchers synthesize compound to flush HIV out of hiding
11. World first: researchers develop completely automated anesthesia system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...holders to be held on January 8, 2009 , , T... International Inc. ("MedEmerg") (OTCBB: MDER), on..., announced today that it has obtained an interim ...oncerning its previously announced plan of arrange...lth Group Inc. ("AIM") will acquire all of MedEmer...
(Date:11/21/2008)...he University of Texas Health Science Center at Ho...ce in Aging Studies (TEXAS), to promote geriatrics...million award from the Donald W. Reynolds Foundati...ll allow us to teach geriatric medicine principles...to practicing physicians. With the reach of Lyndon...
(Date:11/21/2008)... Heska Corporation,(Nas...he New York Society of,Security Analysts, 12th An...ecember 2, 2008 at 1177 Avenue of the Americas, 2n...duled to begin at 9:35 a.m. Eastern Time (7:35 a.m...ebcast and for two weeks,following the presentati...
(Date:11/21/2008)... The Generic,Pharmaceut...tement today from,GPhA President and CEO Kathleen...TC) roundtable on "Emerging Health Care Competitio...at the FTC is conducting this roundtable demonstra...sumers have access to safe and,affordable biogene...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2
...A new study suggests that children with hemophilia...ses joint pain and swelling, are more at risk // ... their later years. But there is hope in preventi...dren, say researchers. Hemophiliac children are no...
...Eighty percent of the time childhood acute lymphob...bad news is doctors are not sure // why it doesn’...new research finds it could be because of a small ...rugs used to treat the disease. Researchers teste...
...A new study finds MRIs are significantly better at...ping cancers than standard mammograms // or clinic...omen with a lifetime breast cancer risk of 15 perc...so carried one of the genes known to put women at ...
...Moms-to-be have one more good reason not to smoke....ing during the early months // of pregnancy increa...e study, involved women from Scotland and England ...ere about six months old. Researchers asked about ...
Other Medicine News:
(Date:11/20/2008)... WASHINGTON, Nov. 20 T...h & Gender Equity: , , WHAT: World AI... , Tuesday, November 25, 2008 , 11:00 a.m. E...trongly encouraged: https://cc.readytalk.com/r/1x...ions outpacing the number of people newly put on t...
(Date:11/20/2008)... , , , , PHILADELPHIA, Nov. 20 /P...K ) today announced that the United States Food an...proval for PROMACTA(R) (eltrombopag) for the treat...immune (idiopathic) thrombocytopenic purpura (ITP)...teroids, immunoglobulins or splenectomy. The appro...
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswir...y that the Anti-infective Drugs Advisory Committee...as voted 17 to 2 against the,approval of intraven...nt for,the treatment of patients with complicated...luding those caused by methicillin-resistant Staph...
(Date:11/20/2008)... EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCal...he company will present results from the Phase 1B,...dvanced metastatic breast,cancer, BZL101, at the ...onal,Conference in Atlanta, Georgia. The Company...g abstract and will be presented as a part of the ...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Minnesota Reaches Milestone in Goal to End Homelessness 28155 1Minnesota Reaches Milestone in Goal to End Homelessness 28155 2NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 1NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 2NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 3Men are better at detecting infidelities 5647 1Men are better at detecting infidelities 5647 2Women at Higher Risk for Pulmonary Hypertension 28144 1Women at Higher Risk for Pulmonary Hypertension 28144 2
...FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Ne...blication in the June 23 issue,of the journal The ...e therapy trial for Parkinson,s disease and the fi...s own brain cells for any adult,neurodegenerative ...in 12 patients with,advanced Parkinson,s disease d...
..."Electroloading of mature dendritic cells with tum...ponse", GAITHERSBURG, Md., and YOKOHAMA, Japan, Ju...net Co., Ltd. announce a,joint poster presentation...ociety for Cellular Therapy. The meeting is being,...presentation is entitled "Electroloading of mature...
Other Medicine Technology:Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 2MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 3
This is adapted to microplate or card.
ScanGel® Incubator
The ID-Micro Typing System™ (ID-MTS) Gel Test is suitable for a broad range of blood bank applications. Applications that include antibody screening and identification, ABO blood grouping and R
...Mini-Vertical Gel System simplifies the process of...AGE format. It is able to run four gels at a time,...tility and throughput, the 120 mini-vertical runs ...120 mini-vertical has a modular design. The basic ...
Medicine Products: